Overview

Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effects of ACE-536 on anemia in patients with low or intermediate-1 risk MDS.
Phase:
Phase 2
Details
Lead Sponsor:
Acceleron Pharma Inc.
Acceleron Pharma, Inc.
Treatments:
Luspatercept